SUBSCRIBE
SUBSCRIBE

Nick Paul Taylor

Nick is a freelance writer who has been reporting on the global life sciences industry since 2008. With a BSc in biology, Nick writes about the science and business of biopharma and medtech for numerous healthcare publications. He can be reached at nick.paul.taylor@gmail.com or on LinkedIn.

Distorted pink piggy bank squeezed in vise , symbolizing financial stress and debt. with plain blue background
Venture capital
Early-Stage Biotechs Feel the Squeeze as Funding Favors Derisked Assets: JPM
Heightened diligence standards and longer decision timelines for early-stage startups slowed venture activity last year, J.P. Morgan found in a report published ahead of the bank’s annual healthcare conference in San Francisco.
January 12, 2026
 · 
2 min read
 · 
Nick Paul Taylor
A look into the future. Concept. stock photo
Manufacturing
2026: Putting the Reindustrialization Mandate Into Practice
Industry leaders are focused on the resilience of key starting material supply and the knock-on effects of automation in the new year.
January 6, 2026
 · 
4 min read
 · 
Nick Paul Taylor
Oct 9, 2019 Milpitas / CA / USA - Johnson & Johnson Vision offices in Silicon Valley; Johnson & Johnson Vision Care, Inc. is part of the American multinational corporation Johnson&Johnson
Immunology and inflammation
J&J Stops Mid-stage Eczema Trial as $1.25B Asset Misses Efficacy Mark
J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action could improve on existing therapies.
January 5, 2026
 · 
2 min read
 · 
Nick Paul Taylor
AbbVie's office in South San Francisco, California
Lung cancer
AbbVie Challenges Amgen With $100M Upfront for Trispecific Lung Cancer Drug
The Illinois-based pharma has committed more than $1 billion in milestones to secure rights to ZG006 and join a who’s who of drugmakers targeting the DLL3 protein.
January 5, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Business growth or increase in professional income, business operations, investment profits or interest on savings, increase in interest rates, businessman holding gold coins forming a growing arrow symbol.
Drug pricing
Pfizer Leads Industry-Wide Surge in Drug Prices for 2026 Despite Political Pressure
More than a dozen pharmas have recently struck deals with the White House to lower drug prices. Nevertheless, drugmakers reportedly plan to raise the U.S. prices of at least 350 branded medications.
January 2, 2026
 · 
2 min read
 · 
Nick Paul Taylor
whale watching boat in Iceland, group of people look at whale
Approvals
Vanda Ends 40-Year Motion Sickness Drug Drought With FDA Approval for Nereus
Jefferies analysts envision a steady launch curve that could ultimately drive meaningful sales from people who are dissatisfied with existing treatments.
January 2, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Recession arrow, Graph showing business decline on led screen
Complete response letters
FDA Rejects Corcept and Outlook Filings, Crushing Stock Prices
Both companies received agency requests for more evidence of the effectiveness of their therapies.
January 2, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Diet pills and bottle of diet supplements with measuring tape
GLP-1
Novo’s Wegovy Pill Wins Obesity Approval, Securing Lead in Oral GLP-1 Race
Analysts called the approval a much-needed win for Novo Nordisk, but warned that the company could struggle to grow sales once rival drugs come to market.
December 23, 2025
 · 
2 min read
 · 
Nick Paul Taylor
vector illustration arrows miss the target board, concept of lost in focus, failure, fail, mistake
Neuroscience
Neurocrine’s Valbenazine Fails Phase III Neurodevelopmental Disorder Trial
Analysts said the outcome is disappointing because there are no approved treatments for dyskinetic cerebral palsy, but the setback had little impact on Neurocrine’s valuation.
December 23, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Abstract creative financial graph with finger clicks on a digital tablet on background, forex and investment concept.
Legal
Investment Banker Accused of Leaking Pharma M&A Secrets in $41M Insider Trading Scheme
The banker allegedly shared details of a series of multibillion-dollar buyouts by companies including AbbVie, GSK and Pfizer.
December 23, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Made in USA, with USA Map. 3D Illustration
Manufacturing
2025: The Year Trump Pushed Manufacturing Into the Spotlight
A push to reshore some drug production and progress in advanced manufacturing technologies have been prominent trends this year, industry leaders say.
December 23, 2025
 · 
4 min read
 · 
Nick Paul Taylor
Money or health. Scale of balance between money, dollar and medicine, pill. Cost of health. Compare of price healthcare and healthy. Seesaw between wealth and healthy. Treatment or savings. Vector.
Drug pricing
Trump Administration Reaches Pricing Agreements With 9 More Drugmakers
Leerink analysts hailed the deals as a sign that President Trump “is unlikely to attack the industry in 2026.”
December 22, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Policy
Disc Shares Slip Amid Report FDA’s Prasad Is Skeptical of Bitopertin’s Efficacy
The biologics center director reportedly became personally involved after the team reviewing the rare blood disorder filing asked for an extension to the CNPV-accelerated timeline.
December 22, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Approvals
Cytokinetics Wins FDA Approval, Clearing Way to Challenge BMS in Heart Disease Market
Stifel analysts said the label for cardiac myosin inhibitor Myqorzo is in line with their expectations and is differentiated compared with BMS’ Camzyos.
December 22, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Checklist
Manufacturing
Big Pharma Pushes FDA To Decouple Inspections From Drug Approval Applications
Representatives of companies including AbbVie, Eli Lilly, Johnson & Johnson and Merck have voiced concerns about the FDA’s approach to pre-approval inspections.
December 16, 2025
 · 
4 min read
 · 
Nick Paul Taylor
Load More